Personalized immunotherapy for stage III lung cancer
Treatments studied
Part of Cancer, Immune system & allergy, Lungs & breathing clinical trials.
This trial tests a personalized immunotherapy approach for people with stage III lung cancer that can't be removed surgically. It combines standard chemoradiation with immunotherapy to see if this improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have stage III non-small cell lung cancer that cannot be removed by surgery.
- You are physically able to do daily activities (score 0 or 1 on a performance scale).
- You are fit to receive chemotherapy and radiation together, with a radiation dose of at least 60 Gy.
- You do not have certain genetic changes in your tumor (like EGFR, ALK, or ROS1 mutations).
- You have not had prior immunotherapy or radiation to the chest.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 3 trial tests whether tailoring the next (add-on) treatments can improve outcomes after standard chemoradiation and immunotherapy for stage III, unresectable (not operable) non-small cell lung cancer. It specifically looks at giving durvalumab plus an additional drug (tremelimumab) and possibly other consolidation chemotherapy based on a personalized plan.
This trial tests a new combination of chemotherapy, radiation, and immunotherapy (durvalumab) for people with stage III non-small cell lung cancer that cannot be removed with surgery. The goal is to see if giving a smaller, more focused radiation dose can be just as effective with fewer side effects.
This trial tests a combination of immunotherapy, chemotherapy, and either surgery or radiation for people with stage IIIA or IIIB non-small cell lung cancer. The goal is to see if adding the drug durvalumab after standard treatment helps control the cancer better.
This trial tests whether giving a combination of an immunotherapy drug (serplulimab) and chemotherapy before any surgery can help shrink tumors in people with stage III lung cancer that can't be removed. The goal is to make the cancer easier to treat and improve outcomes.
This trial tests if giving the immunotherapy drug durvalumab after chemoradiation and surgery helps people with stage 3 non-small cell lung cancer. You will receive standard chemoradiation, then have surgery, and then get durvalumab to see if it lowers the chance of the cancer coming back.
This study tests a drug called pembrolizumab (an immunotherapy that helps your immune system fight cancer) combined with two chemotherapy drugs, without radiation. It is for people with stage III lung cancer that has not spread and has a high PD-L1 level. The goal is to see if this treatment can shrink or control the cancer better than the usual approach.
Hear when a new Non-small Cell Lung Cancer Stage III Unresectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.